Immunome, Inc.

Immunome, Inc. is a clinical-stage oncology company dedicated to the discovery and development of first-in-class and best-in-class targeted cancer therapies. The company's mission is to address high unmet medical needs and improve outcomes for cancer patients through rigorous science and innovative approaches. Headquartered in Bothell, Washington, Immunome specializes in the comprehensive process of discovering, designing, developing, manufacturing, and commercializing advanced oncology therapeutics.

The company's pipeline features several investigational therapeutics, including small molecules, antibody-drug conjugates (ADCs), and radioligand therapies. Key programs include varegacestat (formerly AL102), a late-clinical stage gamma secretase inhibitor for desmoid tumors, which has reported positive topline results from its Phase 3 RINGSIDE trial and has an NDA submission planned. Immunome is also advancing IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial, and IM-3050, a FAP-targeted radioligand therapy that has received IND clearance for a planned Phase 1 study. Additionally, its preclinical pipeline includes ADC candidates such as IM-1617, IM-1340, and IM-1335, targeting various solid tumors, with IM-1617 recently entering a Phase 1 trial.

Immunome's leadership is spearheaded by President and CEO Clay Siegall, Ph.D., who assumed the role in October 2023 following the company's merger with Morphimmune Inc. Dr. Siegall brings extensive experience from his tenure as co-founder and leader of Seagen, which was acquired by Pfizer for $43 billion. Recent notable developments include the dosing of the first patient in a Phase 1 trial for IM-1617 in June 2026, the presentation of detailed Phase 3 RINGSIDE data for Varegacestat at the 2026 ASCO Annual Meeting in May 2026, and the submission of a New Drug Application to the U.S. FDA for Varegacestat in April 2026. The company's strategic focus remains on leveraging its expertise to build a broad and differentiated portfolio of targeted oncology therapeutics.